3,487.66p+59.66 (+1.74%)27 Jun 2022, 12:23
Jump to:
Dechra Pharmaceuticals PLC Fundamentals
Company Name | Dechra Pharmaceuticals PLC | Last Updated | 2022-06-27 |
---|---|---|---|
Industry | Drug Manufacturers - General | Sector | Healthcare |
Shares in Issue | 108.389 m | Market Cap | £3.77 bn |
PE Ratio | 51.28 | Dividend per Share | £0.35 |
Dividend Yield | 1.21 | Dividend Cover | 1.45 |
EPS | £0.51 | EPS Growth (%) | 0.33 |
PEG | 0 | DPS Growth (%) | 0.0840 |
Debt Ratio | 0.2690 | Debt Equity Ratio | 0.4908 |
Asset Equity Ratio | 1.8427 | Cash Equity Ratio | 0.1936 |
Quick Ratio | 1.6200 | Current Ratio | 2.91 |
Price To Book Value | 5.8140 | ROCE | 0 |
Dechra Pharmaceuticals PLC Dividends
Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
---|---|---|---|---|---|
Interim | 2022-03-03 | 2022-04-07 | GBP | 0.1200 | |
Prelim | 2021-10-28 | 2021-11-19 | GBP | 0.2939 | |
Interim | 2021-03-04 | 2021-04-07 | GBP | 0.1111 | |
Prelim | 2020-11-05 | 2020-11-27 | GBP | 0.2400 | |
Interim | 2020-03-05 | 2020-04-08 | GBP | 0.1029 | |
Prelim | 2019-10-24 | 2019-11-15 | GBP | 0.2210 |
Dechra Pharmaceuticals PLC Company Financials
Assets | 2021 | 2020 | 2019 |
---|---|---|---|
Tangible Assets | £87.00 m | £76.40 m | £58.40 m |
Intangible Assets | £715.80 m | £692.20 m | £680.60 m |
Investments | £17.10 m | £17.40 m | £10.10 m |
Total Fixed Assets | £821.90 m | £788.70 m | £750.00 m |
Stocks | £149.50 m | £120.80 m | £103.50 m |
Debtors | £106.70 m | £93.90 m | £99.80 m |
Cash & Equivalents | £118.40 m | £227.40 m | £80.30 m |
Other Assets | £2.00 m | £2.70 m | £900,000.00 |
Total Assets | £1.21 bn | £1.24 bn | £1.04 bn |
Liabilities | 2021 | 2020 | 2019 |
---|---|---|---|
Creditors within 1 year | £155.80 m | £137.30 m | £118.10 m |
Creditors after 1 year | £425.40 m | £462.80 m | £414.30 m |
Other Liabilities | 0 | 0 | 0 |
Total Liabilities | £581.20 m | £600.10 m | £532.40 m |
Net assets | £632.90 m | £637.50 m | £509.10 m |
Equity | 2021 | 2020 | 2019 |
---|---|---|---|
Called up share capital | £1.10 m | £1.10 m | £1.00 m |
Share Premium | £411.60 m | £409.30 m | £277.90 m |
Profit / Loss | £74.00 m | £40.90 m | £27.80 m |
Other Equity | £632.90 m | £637.50 m | £509.10 m |
Preference & Minorities | 0 | 0 | 0 |
Total Capital Employed | £632.90 m | £637.50 m | £509.10 m |
Ratios | 2021 | 2020 | 2019 |
---|---|---|---|
Debt Ratio | £0.33 | £0.35 | £0.38 |
Debt-to-Equity | £0.50 | £0.55 | £0.60 |
Assets / Equity | 1.8427 | 1.8427 | 1.8427 |
Cash / Equity | 0.1936 | 0.1936 | 0.1936 |
EPS | £0.53 | £0.40 | £0.36 |
Cash Flow | 2021 | 2020 | 2019 |
---|---|---|---|
Cash from operating activities | £89.10 m | £106.40 m | £81.80 m |
Cashflow before financing | £34.00 m | £225.30 m | £61.70 m |
Increase in Cash | -£102.10 m | £143.80 m | -£200,000.00 |
Income | 2021 | 2020 | 2019 |
---|---|---|---|
Turnover | £608.00 m | £515.10 m | £481.80 m |
Cost of sales | £262.10 m | £223.50 m | £208.70 m |
Gross Profit | £345.90 m | £291.60 m | £273.10 m |
Operating Profit | £84.00 m | £52.20 m | £39.00 m |
Pre-Tax profit | £74.00 m | £40.90 m | £27.80 m |
Dechra Pharmaceuticals PLC Company Background
Sector | Healthcare |
---|---|
Activities | Dechra Pharmaceuticals PLC is a major drug manufacturing company with a focus on veterinary pharmaceutical products. The company develops, manufactures, and markets its products exclusively for veterinarians globally. Dechra is structured along three segments, including being European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The vast majority of Dechra's revenue is generated in Europe, followed by the U.S. Dechra derives most of its revenue through its Companion Animal Product category, followed by food-producing animal products. |
Latest Interim Date | 21 Feb 2022 |
Latest Fiscal Year End Date | 6 Sep 2021 |
Dechra Pharmaceuticals PLC Directors
Appointed | Name | Position |
---|---|---|
2021-09-14 | Mr. Julian Heslop | Non-Executive Director |
2013-10-17 | Mr. Neil W Warner | Non-Executive Director |
2009-01-09 | Mr. Malcolm McDonald Diamond MBE | Non-Executive Director |
2019-09-05 | Mr. Richard John Cotton | Executive Director,Chief Financial Officer |
2022-06-13 | Mr. Ian David Page | Executive Director,Chief Executive |
2016-10-21 | Mr. Michael Redmond | Non-Executive Director,Chairman |
2021-12-29 | Mr. William Anthony Rice | Non-Executive Director,Chairman |
2021-09-14 | Ms. Ishbel Jean Stewart Macpherson | Non-Executive Director,Senior Independent Non-Executive Director |
2015-09-09 | Ms. Zoe Goulding | Company Secretary |
2012-10-19 | Mr. Simon David Evans | Executive Director,Group Finance Director |
2014-09-15 | Mr. Edwin Thomas William Torr | Executive Director,MD, Dechra Veterinary Products Europe |
2012-07-09 | Mr. Bryan Geoffrey Morton | Non-Executive Director |
2016-04-08 | Dr. Christopher Gareth Joseph Richards | Non-Executive Director |
2022-04-05 | Ms. Alison Elizabeth Platt | Non-Executive Director,Chairman |
2021-10-06 | Mr. Paul Sandland | Executive Director,Chief Financial Officer |
2021-09-22 | Mr. Anthony Griffin | Executive Director,Managing Director, Dechra Veterinary Products EU |
2017-09-05 | Ms. Anne-Francoise Nesmes | Executive Director,Chief Financial Officer |
2021-09-14 | Dr. Lawson Macartney | Non-Executive Director |
2021-09-14 | Ms. Lisa Bright | Non-Executive Director |
2022-02-21 | Ms. Denise Goode | Non-Executive Director |
Dechra Pharmaceuticals PLC Contact Details
Company Name | Dechra Pharmaceuticals PLC |
---|---|
Address | 24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, CW9 7UA |
Telephone | +44 1606814730 |
Website | http://www.dechra.com |
Dechra Pharmaceuticals PLC Advisors
Auditor | PricewaterhouseCoopers LLP |
---|---|
Phone | +44 1212655000 |
Fax | +44 1212655050 |
Bank | Royal Bank of Scotland PLC |
---|
Registrar | Equiniti Limited |
---|
Remuneration Consultant | Deloitte LLP |
---|---|
Phone | +44 2079363000 |
Fax | +44 2075831198 |
Financial PR Adviser | Tooleystreet Communications |
---|
Solicitor | DLA Piper LLP |
---|---|
Phone | +44 8700111111 |
Fax | +44 1212625794 |
Stockbroker | Investec Securities |
---|---|
Phone | +44 2075974000 |
Fax | +44 2075974070 |
Financial Adviser | Investec Investment Banking |
---|---|
Phone | +44 2075974000 |
Fax | +44 20 75974070 |
Bank | HSBC Bank PLC |
---|
Bank | Barclays Bank PLC |
---|
Sign up to our
daily email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine

Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
Company | Price | % Chg |
---|---|---|
Molten Ventures PLC | 467.00 | 5.23 |
Abrdn Private Equity Opportunities Trust PLC | 471.00 | 5.13 |
Tui AG | 153.20 | 4.97 |
Easyjet PLC | 413.00 | 4.58 |
Blackrock World Mining Trust PLC | 616.00 | 4.41 |
Ferrexpo PLC | 146.00 | 4.29 |
Fallers
Company | Price | % Chg |
---|---|---|
Helios Towers PLC | 122.80 | -2.38 |
Abrdn PLC | 167.60 | -1.96 |
Jupiter Fund Management PLC | 158.00 | -1.56 |
Energean PLC | 1,136.00 | -1.47 |
Drax Group PLC | 645.00 | -1.45 |
Biffa PLC | 401.40 | -1.38 |